文献速递神经肿瘤

RARRES2在异柠檬酸脱氢酶1突变型胶质瘤患者中表达下调并作为胶质瘤的不良预后因素

RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
PubMed 文献 · World Neurosurg · 2023-06-02

该研究利用公共胶质瘤队列分析IDH1突变介导的转录和DNA甲基化改变,发现RARRES2在IDH1野生型低级别胶质瘤中上调且高表达与更差临床结局相关,IDH1突变诱导广泛DNA高甲基化使RARRES2下调,RARRES2低甲基化是低级别胶质瘤的不良预后因素。

要点

  • RARRES2在IDH1野生型低级别胶质瘤中上调,高表达与更差临床结局相关。
  • IDH1突变诱导低级别胶质瘤和胶质母细胞瘤中广泛DNA高甲基化,下调基因过半由高甲基化贡献。
  • RARRES2在IDH1突变型低级别胶质瘤或胶质母细胞瘤中高甲基化,其低甲基化是低级别胶质瘤不良预后因素。

核心结论

  • RARRES2受IDH1突变下调,并作为胶质瘤的不良预后因素。

研究设计与样本

  • 收集公共胶质瘤队列并使用R软件处理,用热图展示IDH1突变介导的转录改变,用TBtools重叠IDH1突变型胶质瘤中的差异表达基因,用Kaplan-Meier生存分析确定IDH1调控基因的预后效应。

主要发现

  • RARRES2在IDH1野生型低级别胶质瘤患者中上调,且RARRES2表达水平较高与低级别胶质瘤更差临床结局相关。
  • IDH1野生型低级别胶质瘤患者中RARRES2表达水平较高者总生存更差。
  • 与低级别胶质瘤相比,RARRES2在IV级胶质瘤(胶质母细胞瘤)中上调,且RARRES2是胶质瘤的不良预后因素。
  • 在胶质母细胞瘤中,RARRES2也与IDH1突变相关。
  • 在低级别胶质瘤和胶质母细胞瘤中,IDH1突变均诱导广泛DNA高甲基化,IDH1突变型胶质瘤中下调基因超过一半由DNA高甲基化贡献。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) induce extensive transcriptional alterations to promote glioma development. However, IDH1 mutation contributes the better clinical outcomes of glioma. Further understanding the transcriptional and DNA methylation changes mediated by IDH1 mutation will provide new therapeutic targets for glioma. METHODS: Public glioma cohorts were collected and processed using R software. The transcriptional changes mediated by IDH1 mutation were determined and presented using heatmap. The differentially expressed genes in IDH1 mutant glioma were overlapped using TBtools. The prognostic effects of IDH1 regulated genes were determined by Kaplan-Meier survival analysis. RESULTS: Retinoic acid receptor responder 2 (RARRES2) was upregulated in IDH1 wild type lower-grade glioma (LGG) patients, and higher expression levels of RARRES2 were associated with worse clinical outcomes of LGG. Moreover, IDH1 wild type LGG patients with higher expression levels of RARRES2 had even worse overall survival. Compared with LGG, RARRES2 was upregulated in grade IV glioma (glioblastoma multiforme, GBM). Also, RARRES2 represented an unfavorable prognostic factor of glioma. In GBM, RARRES2 was also associated with IDH1 mutation. In both LGG and GBM, IDH1 mutation induced extensive DNA hypermethylation, and more than half genes that were downregulated in IDH1 mutant glioma were contributed by DNA hypermethylation. RARRES2 was also hypermethylated in IDH1 mutant LGG or GBM patients. Furthermore, RARRES2 hypomethylation was an unfavorable prognostic factor in patients with LGG. CONCLUSIONS: RARRES2 was downregulated by IDH1 mutation and served as an unfavorable prognostic factor in glioma.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang H, Wang X, Xu L, et al. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma. World Neurosurg. 2023. PMID: 37271257. doi:10.1016/j.wneu.2023.05.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。